Literature DB >> 2301005

Evidence that anti-asialo GM1 in vivo improves engraftment of T cell-depleted bone marrow in hybrid recipients.

J L Ferrara1, P Mauch, P J Van Dijken, K E Crosier, J Michaelson, S J Burakoff.   

Abstract

Engraftment of T cell-depleted bone marrow was studied in a P----F1 murine bone marrow transplant model which features long-term stability of mixed chimerism of donor (B6) and host (B6AF1) cells after BMT. We report that a polyclonal antibody to asialo GM1 (anti-ASGM1) given in vivo after transplant was able to increase long-term donor bone marrow engraftment. In vivo anti-ASGM1 eliminated NK activity but did not affect the generation of cytotoxic T cells nor did it stimulate hematopoiesis in vitro. Anti-Thy 1.2, a pan-T cell monoclonal antibody, had no effect on donor engraftment. We conclude that ASGM1+ cells with NK activity inhibit the long-term engraftment of bone marrow stem cells in this model and that antibodies to NK cells can be used in vivo as an effective component of the transplant conditioning regimen.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2301005     DOI: 10.1097/00007890-199001000-00030

Source DB:  PubMed          Journal:  Transplantation        ISSN: 0041-1337            Impact factor:   4.939


  1 in total

1.  Bone marrow produces sufficient alloreactive natural killer (NK) cells in vivo to cure mice from subcutaneously and intravascularly injected 4T1 breast cancer.

Authors:  Michel van Gelder; Ariane Vanclée; Catharina H M J van Elssen; Pierre Hupperets; Lotte Wieten; Gerard M Bos
Journal:  Breast Cancer Res Treat       Date:  2016-12-03       Impact factor: 4.872

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.